Charles River Laboratories Inte (CRL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Charles River Laboratories Inte

NYSE•Healthcare•Diagnostics & Research

$281.67+8.26(0.03%)After hours

Market Cap

$13.36B

P/S

3.3x

P/B

4.7x

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

How this company scores

WeakMetricSide Score: 39/100

Strongest: Cash & Earnings Quality (15/25); weakest: Profitability (4/25).

Profitability4/25

Growth8/25

Balance Sheet & Red Flags12/25

Cash & Earnings Quality15/25

Strengths

Cash-backed earningsNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 428.8x5y range 20.8x – 428.8x

Currently above its 14-quarter median.

P/S · 3.3x5y range 1.8x – 6.7x

Currently above its 20-quarter median.

P/B · 4.7x5y range 2.1x – 9.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 27.9% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $13.36B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $4.00B
Q. Revenue: $1.00B
TTM EBITDA: $388.03M
TTM Op. Income: $90.14M
Q. Op. Income: $119.89M
TTM Net Income: $-238.46M
Q. Net Income: $-1.48M
EPS: $-0.03
Shares Out.: $48.02M

$4.00B in TTM revenue declined 0.7% YoY, reaching $1.00B last quarter. TTM EBITDA of $388.03M and TTM operating income of $90.14M show growth is flowing through to the bottom line. However, net income is negative at $238.46M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 1% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 45.0%
EBITDA Margin: 18.6%
Op. Margin: 11.9%
Net Margin: -0.1%

Op. margin of 11.9% is up 2.2% YoY — cost efficiency is improving. Net margin at -0.1% and gross margin of 45.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 23% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 3.3x
P/B Ratio: 4.7x

P/S of 3.3x and P/B of 4.7x. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $7.53B
Cash: $192.03M
Long-Term Debt: $2.62B
Book Value: $2.84B
D/E Ratio: 0.9
Debt/EBITDA: 14.0

With $7.53B in assets and $2.62B in long-term debt, D/E is 0.9and book value is $2.84B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 3 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $179.72M
TTM Free Cash Flow: $370.61M
FCF Margin: 9.3%
FCF / Net Income: -1.6

TTM FCF of $370.61M on $179.72M in operating cash flow. The FCF / Net Income ratio of -1.6x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has fallen for 4 consecutive quarters — a weakening trend.